AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Accordingly, AnGes MG will soon start a phase I clinical trial by signing trial contracts with medical institutions. Specifically, the proposed clinical trial will seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the field of atopic dermatitis.
In addition, AnGes MG has partnered with Alfresa Pharma and jointly conducted research on NF-kappa B decoy oligodeoxynucleotide, aiming to apply it to atopic dermatitis.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jul 27, 2005|
|Previous Article:||Kobelco Eco-Solutions Develops Fuel Gas Generator That Uses Sewage Sludge.|
|Next Article:||Chisso, Kobe University to Create New Company for Thermoresponsive Magnetic Nanoparticle Therma-Max.|